221 related articles for article (PubMed ID: 22699438)
1. Hepatitis E vaccine development: a 14 year odyssey.
Wu T; Li SW; Zhang J; Ng MH; Xia NS; Zhao Q
Hum Vaccin Immunother; 2012 Jun; 8(6):823-7. PubMed ID: 22699438
[TBL] [Abstract][Full Text] [Related]
2. Toward the development of a hepatitis E vaccine.
Kamili S
Virus Res; 2011 Oct; 161(1):93-100. PubMed ID: 21620908
[TBL] [Abstract][Full Text] [Related]
3. Development of new hepatitis E vaccines.
Cao Y; Bing Z; Guan S; Zhang Z; Wang X
Hum Vaccin Immunother; 2018; 14(9):2254-2262. PubMed ID: 29708836
[TBL] [Abstract][Full Text] [Related]
4. Lessons from hepatitis E vaccine design.
Li S; Zhang J; Xia N
Curr Opin Virol; 2015 Apr; 11():130-6. PubMed ID: 25913817
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.
Zhu FC; Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Wang H; Yang CL; Jiang HM; Cai JP; Wang YJ; Ai X; Hu YM; Tang Q; Yao X; Yan Q; Xian YL; Wu T; Li YM; Miao J; Ng MH; Shih JW; Xia NS
Lancet; 2010 Sep; 376(9744):895-902. PubMed ID: 20728932
[TBL] [Abstract][Full Text] [Related]
6. Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®).
Zhang X; Wei M; Pan H; Lin Z; Wang K; Weng Z; Zhu Y; Xin L; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2014 Jul; 32(32):4039-50. PubMed ID: 24892250
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation.
Li Y; Huang X; Zhang Z; Li S; Zhang J; Xia N; Zhao Q
Viruses; 2020 Jan; 12(1):. PubMed ID: 31963175
[TBL] [Abstract][Full Text] [Related]
8. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
[TBL] [Abstract][Full Text] [Related]
9. Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods.
Zhang X; Wei M; Sun G; Wang X; Li M; Lin Z; Li Z; Li Y; Fang M; Zhang J; Li S; Xia N; Zhao Q
Vaccine; 2016 Nov; 34(48):5871-5877. PubMed ID: 27793484
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis E virus: Current epidemiology and vaccine.
Wu X; Chen P; Lin H; Hao X; Liang Z
Hum Vaccin Immunother; 2016 Oct; 12(10):2603-2610. PubMed ID: 27184971
[TBL] [Abstract][Full Text] [Related]
11. Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity.
Zhang J; Zhang XF; Zhou C; Wang ZZ; Huang SJ; Yao X; Liang ZL; Wu T; Li JX; Yan Q; Yang CL; Jiang HM; Huang HJ; Xian YL; Shih JW; Ng MH; Li YM; Wang JZ; Zhu FC; Xia NS
Clin Microbiol Infect; 2014 Jun; 20(6):O397-405. PubMed ID: 24118636
[TBL] [Abstract][Full Text] [Related]
12. Development of the hepatitis E vaccine: from bench to field.
Zhang J; Shih JW; Wu T; Li SW; Xia NS
Semin Liver Dis; 2013 Feb; 33(1):79-88. PubMed ID: 23564392
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity.
Zhang J; Li SW; Wu T; Zhao Q; Ng MH; Xia NS
Rev Med Virol; 2012 Sep; 22(5):339-49. PubMed ID: 22645002
[TBL] [Abstract][Full Text] [Related]
14. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection.
Kamili S; Spelbring J; Carson D; Krawczynski K
J Infect Dis; 2004 Jan; 189(2):258-64. PubMed ID: 14722891
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis: Hepatitis E vaccination--is HEV 239 the breakthrough?
Wedemeyer H; Pischke S
Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):8-10. PubMed ID: 21212772
[No Abstract] [Full Text] [Related]
16. Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.
Zhao Q; Zhang J; Wu T; Li SW; Ng MH; Xia NS; Shih JW
J Gastroenterol; 2013 Feb; 48(2):159-68. PubMed ID: 23149436
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of a hepatitis E vaccine.
Zhang J; Zhang XF; Huang SJ; Wu T; Hu YM; Wang ZZ; Wang H; Jiang HM; Wang YJ; Yan Q; Guo M; Liu XH; Li JX; Yang CL; Tang Q; Jiang RJ; Pan HR; Li YM; Shih JW; Ng MH; Zhu FC; Xia NS
N Engl J Med; 2015 Mar; 372(10):914-22. PubMed ID: 25738667
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
Yu XY; Chen ZP; Wang SY; Pan HR; Wang ZF; Zhang QF; Shen LZ; Zheng XP; Yan CF; Lu M; Chen B; Zheng Y; Zhang J; Lv HK; Huang SJ
Vaccine; 2019 Jul; 37(32):4581-4586. PubMed ID: 31262585
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
[TBL] [Abstract][Full Text] [Related]
20. Progress in the Production of Virus-Like Particles for Vaccination against Hepatitis E Virus.
Mazalovska M; Kouokam JC
Viruses; 2020 Jul; 12(8):. PubMed ID: 32751441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
